Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

D5817

Sigma-Aldrich

DMXAA

≥98% (HPLC), solid, apoptosis inducer

Synonym(e):

5,6-Dimethylxanthenone-4-acetic Acid, ASA404, Vadimezan

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Größe auswählen

5 MG
€ 243,00
25 MG
€ 829,00

€ 243,00

Check Cart for Availability
Bulk-Bestellung anfordern
Alle Fotos(1)

Größe auswählen

Ansicht ändern
5 MG
€ 243,00
25 MG
€ 829,00

About This Item

Empirische Formel (Hill-System):
C17H14O4
CAS-Nummer:
117570-53-3
Molekulargewicht:
282.29
MDL-Nummer:
MFCD00870555
UNSPSC-Code:
12352200
PubChem Substanz-ID:
24724464
NACRES:
NA.77

€ 243,00

Check Cart for Availability
Bulk-Bestellung anfordern

Produktbezeichnung

DMXAA, ≥98% (HPLC), solid

Qualitätsniveau

100

Assay

≥98% (HPLC)

Form

solid

Farbe

light brown

Löslichkeit

DMSO: soluble >10 mg/mL

Lagertemp.

2-8°C

SMILES String

Cc1ccc2C(=O)c3cccc(CC(O)=O)c3Oc2c1C

InChI

1S/C17H14O4/c1-9-6-7-13-15(20)12-5-3-4-11(8-14(18)19)17(12)21-16(13)10(9)2/h3-7H,8H2,1-2H3,(H,18,19)

InChIKey

XGOYIMQSIKSOBS-UHFFFAOYSA-N

Allgemeine Beschreibung

5,6-dimethylxanthenone-4-acetic acid (DMXAA) is a flavone acetic acid derivative.[1] It acts as a vascular disrupting agent (VDA), which damages tumor vasculature and stimulates an anti-tumor immune response.[2] It stimulates hemorrhagic necrosis.[1]

Anwendung

5,6-dimethylxanthenone-4-acetic acid (DMXAA) has been used to induce type-I IFN signaling in a stimulator of interferon genes (STING) dependent manner.[3][4] It has also been used to study STING-dependent signaling in the absence of infection.[5]

Biochem./physiol. Wirkung

DMXAA is an apoptosis inducer; anti-vascular.

Leistungsmerkmale und Vorteile

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Piktogramme

Exclamation markEnvironment
GHS07,GHS09

Signalwort

Warning

H-Sätze

H302,H400

Gefahreneinstufungen

Acute Tox. 4 Oral - Aquatic Acute 1

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
0000409773
0000409771
0000409773
0000409771
0000248660

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Jing Sun et al.
Biochemical pharmacology, 82(9), 1175-1185 (2011-08-09)
The small molecule anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA, now called Vadimezan) is a potent macrophage and dendritic cell activating agent that, in the murine system, results in the release of large amounts of cytokines and chemokines. The mechanisms by which
Z G Fridlender et al.
British journal of cancer, 108(6), 1288-1297 (2013-03-14)
Successful immunotherapy will require alteration of the tumour microenvironment and/or decreased immune suppression. Tumour-associated macrophages (TAMs) are one major factor affecting tumour microenvironment. We hypothesised that altering TAM phenotype would augment the efficacy of immunotherapy. We and others have reported
S M Tijono et al.
British journal of cancer, 108(6), 1306-1315 (2013-03-14)
Species selectivity of DMXAA (5,6-dimethylxanthenone-4-acetic acid, Vadimezan) for murine cells over human cells could explain in part the recent disappointing phase III trials clinical results when preclinical studies were so promising. To identify analogues with greater human clinical potential, we
Primo N Lara et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(22), 2965-2971 (2011-06-29)
This phase III trial was conducted to test whether the novel vascular disrupting agent ASA404 (vadimezan), when combined with first-line platinum-based chemotherapy, improves survival in patients with advanced non-small-cell lung cancer (NSCLC) versus chemotherapy alone. Patients with advanced stage IIIB
Activation of cGAS-dependent antiviral responses by DNA intercalating agents
Pepin G, et al.
Nucleic Acids Research, 45(1), 198-205 (2016)
Alle zugehörigen Dokumente anzeigen

Artikel

Discover Bioactive Small Molecules for Cell Cycle

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Bioactive Molecules for Apoptosis

Apoptosis regulation involves multiple pathways and molecules for cellular homeostasis.

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.